NasdaqCM - Delayed Quote • USD
KALA BIO, Inc. (KALA)
At close: May 28 at 4:00 PM EDT
After hours: May 28 at 7:24 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 1 |
| Avg. Estimate | -4.4 | -4.53 | -14.49 | -7.57 |
| Low Estimate | -4.58 | -4.89 | -15.37 | -7.57 |
| High Estimate | -4.23 | -4.17 | -13.61 | -7.57 |
| Year Ago EPS | -4.36 | -3.41 | -17.35 | -14.49 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -3.19 | -2.15 | -3.62 | -2.89 |
| EPS Actual | -4.36 | -3.41 | -3.18 | -4.19 |
| Difference | -1.17 | -1.26 | 0.44 | -1.3 |
| Surprise % | -36.70% | -58.60% | 12.20% | -45.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -4.4 | -4.53 | -14.49 | -7.57 |
| 7 Days Ago | -4.4 | -4.53 | -14.49 | -7.57 |
| 30 Days Ago | -2.86 | -3.09 | -10.17 | -11.5 |
| 60 Days Ago | -3.62 | -3.23 | -11.86 | -11.5 |
| 90 Days Ago | -3.62 | -3.23 | -11.86 | -11.5 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | -- |
Growth Estimates
| CURRENCY IN USD | KALA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -0.90% | -- | -- | 7.90% |
| Next Qtr. | -32.80% | -- | -- | 10.20% |
| Current Year | 16.50% | -- | -- | 4.80% |
| Next Year | 47.80% | -- | -- | 12.50% |
| Next 5 Years (per annum) | 40.90% | -- | -- | 11.27% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 5/17/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/2/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 4/1/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/17/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/11/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 5/10/2023 |
Related Tickers
PALI Palisade Bio, Inc.
4.7600
-3.05%
CTMX CytomX Therapeutics, Inc.
1.7900
+2.29%
GBIO Generation Bio Co.
3.0700
0.00%
AVRO AVROBIO, Inc.
1.4800
-1.99%
PRTA Prothena Corporation plc
19.95
-0.45%
ETNB 89bio, Inc.
8.32
+2.21%
ALXO ALX Oncology Holdings Inc.
12.56
-4.63%
SPRB Spruce Biosciences, Inc.
0.6776
-2.85%
CORT Corcept Therapeutics Incorporated
31.61
+14.86%
MRSN Mersana Therapeutics, Inc.
2.4000
+0.84%